Dewpoint Therapeutics Collaborated with Novo Nordisk to Identify Small Molecule Drugs for Insulin Resistance and Diabetes Progression
Shots:
- Dewpoint to receive ~$55M up front, research funding & research milestones across 2 programs, ~$690M in clinical, commercial & sales milestones, and ~$107.5M in total milestones per product along with royalties across 2 commercial products, if Novo Nordisk decides other modalities for the condensates
- Novo Nordisk uses Dewpoint's discovery platform related to biomolecular condensates & identifies drug candidates. The collaboration combines Novo Nordisk's leadership with Dewpoint's groundbreaking discovery & AI technology platform to identify modulators of biomolecular condensates
- Novo Nordisk will also discover non-small molecule drugs against identified condensates using Novo Nordisk capabilities & obtain rights to develop & commercialize potential drugs
Ref: PRNewswire | Image: Dewpoint Therapeutics
Related News:- Merck Signs an Exclusive Agreement with Dewpoint Therapeutics to Develop Curative Treatment for HIV
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
